Pierre Arsène

When Nature Reviews Clinical Oncology (IF = 65) highlights your technology, it is a good sign🔬

@leecronin @curleecronin quantum superposition

With AI I can be both @leecronin and @curleecronin

@leecronin surface of black holes: matter disappears, information persists?

Data emerges from matter.

@leecronin what about prime numbers?

✨ We are pleased that Mursla Bio’s core technology was recently featured on @RevvityInc (NYSE: RVTY) website, highlighting its unique precision diagnostic capabilities. The article discusses how Mursla’s approach to isolating organ-specific extracellular vesicles (EVs) from plasma helps overcome a critical challenge in EV and microRNA research. Notably: - In blood, almost all EVs originate from hematopoietic cells, drowning out signals from solid organs. - Following the enrichment for hepatocyte-derived EVs by Mursla's technology, small RNA-seq libraries revealed microRNA species tightly linked to liver biology and liver cancer that were invisible in bulk EVs. This is especially timely as microRNA biology was honored with the 2024 Nobel Prize in Medicine, underscoring its power as a key regulator of gene expression and as a relevant biomarker class. Revvity concludes that: - Organ-specific EVs deliver quality and biological resolution, unlike bulk EVs that only provide quantity. - They enable signals from defined tissues to emerge by analogy to single-cell sequencing, - This sets a new standard for reliable, multi-omic liquid biopsies with true biological interpretability. This capability underpins Mursla Bio’s AI Precision Medicine Platform, which contributed to the development of EvoLiver™, our first product for liver cancer surveillance. Check out the full post here: lnkd.in/eUS4C9_m More details on our NEXPLOR technology can be found in our recent preprint: lnkd.in/dXk54iyS

🧬 Mursla Bio was recently featured in a new article by @statnews , as a leading company that’s supporting the shift to extracellular vesicles (EVs) for early cancer detection. The article explains why many experts are looking beyond DNA-based blood tests. DNA is often present at low levels in early disease and breaks down easily, making detection difficult. EVs offer a compelling alternative. They are released by living cells and carry stable, information-rich cargo that reflects their tissue of origin, helping address critical gaps in test sensitivity and specificity. Our first product, EvoLiver™, designed for the early detection of liver cancer, is based on our breakthrough platform that isolates organ specific EVs from blood. Our platform can be extended to support broader applications in AI enabled precision medicine across oncology, cardiometabolic diseases, and neurology. Read the article here: statnews.com//2025/07/29/ea… [paywall]

Extracellular Vesicle Diagnostic Platform Launched by Mursla Bio @Mursla uses #extracellularvesicle data to diagnose and monitor #livercancer more precisely than other available methods @Pierre_Arsen #AI hubs.li/Q03svDHx0

🧠 Introducing the Mursla Bio AI Precision Medicine Platform Mursla Bio is proud to announce the launch of its AI Precision Medicine Platform, a full-stack solution enabling organ-specific, multi-omic analysis from blood to advance precision diagnostics and patient stratification. Built on Mursla’s patented extracellular vesicle (EV) technology, the platform enables the isolation of tissue-specific EVs from just 2 milliliters of plasma. It delivers structured, biologically labelled multi-omic data from specific tissues that can drive biomarker discovery, predictive model development, and diagnostic translation. The platform has been validated in a newly released pre-print, developed in collaboration with @Evotec International and University College London (@ucl ). The study demonstrates what we believe to be the most comprehensive scientific validation to date of tissue-EV isolation from a specific human tissue (hepatocytes). Platform highlights: • Patented workflows for tissue-specific EV isolation and biomarker capture • Embedded AI pipelines for multi-omic biomarker discovery and predictive modelling • Proprietary assay formats compatible with standard laboratory instruments • Built for regulatory-grade, scalable diagnostic deployment The platform powers Mursla’s lead program, EvoLiver™, an early disease detection test for liver cancer surveillance in high-risk patients. EvoLiver has received FDA Breakthrough Device Designation. We are now opening access to the platform for strategic collaborations in oncology, cardiometabolic, pulmonary, and neurological diseases. Read the pre-print: biorxiv.org/content/10.110… Read the press release: mursla.com/mursla-bio-int… For partnering enquiries, contact us at: contact@mursla.com #PrecisionMedicine #ArtificialIntelligence #LiquidBiopsy #Diagnostics #EVScience #Biomarkers #MurslaBio #TissueSpecific #MultiOmics #NonInvasive

We are proud to announce that EvoLiver™, Mursla Bio’s flagship test for liver cancer surveillance, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The FDA awards Breakthrough Device Designation to a select number of medical devices that offer a more effective diagnosis of life-threatening diseases and represent a significant advancement over existing solutions. The Designation will support priority review, early feedback and more frequent FDA interactions to obtain FDA approved status for EvoLiver™, broadening its market reach and expediting commercial adoption. This follows the announcement of our latest clinical results at AASLD Liver Meeting in San Diego, CA in which EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies. We are currently progressing towards the launch of EvoLiver™ as a Laboratory Developed Test (LDT), while also advancing our plans for FDA approval via the PMA pathway, which will enable broader clinical adoption and scale-up. Check out our press release here: mursla.com/mursla-fda-rec… #FDA #BreakthroughDeviceDesignation #MurslaBio #EvoLiver #Diagnostics #EVscience #DynamicBiopsy #LiquidBiopsy

🎉 We are thrilled to share that Mursla Bio has been shortlisted for TWO awards at the 2025 Cambridge Independent (@CambridgeIndy) Science and Technology Awards – The Award for Innovation and MedTech Company of the Year! Being recognised in Cambridge—one of the most vibrant and competitive biotech ecosystems in Europe and globally—is especially meaningful, and sets us on the right path globally as we prepare for our next phase of growth. This recognition is a fantastic endorsement of our vision to transform liver cancer surveillance through EvoLiver™, our Dynamic Biopsy-based blood test powered by organ-specific hepatocyte extracellular vesicles. Check out the full list of finalists: cambridgeindependent.co.uk/business/final… #MurslaBio #CambridgeIndependent #ExtracellularVesicles #EVScience #MedTech #Innovation #LiquidBiopsy

BioCentury's latest Emerging Company Profile features @Mursla, which is using extracellular vesicles to detect cancer. Led by ex-banker Pierre Arsène, the company's first goal is surveillance of cirrhosis patients at risk of liver cancer buff.ly/3PDLQ78

𝐓𝐡𝐞 𝐋𝐢𝐯𝐞𝐫 𝐌𝐞𝐞𝐭𝐢𝐧𝐠: @Mursla presented data suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity. #TLM24 Full video: biotechtv.com/post/mursla-bi…

🚀 Mursla Bio Expands to the US with New Office in Cambridge, MA! 🚀 We are thrilled to announce our expansion into the US market with a new office in Cambridge, Massachusetts! This marks a major step in transforming cancer diagnosis and treatment through our novel liquid biopsy tests based on extracellular vesicle (EV) technology. The new office, located in the dynamic biotech ecosystem of the Boston area will enhance Mursla Bio's ability to innovate and collaborate within the liquid biopsy field. This strategic positioning is pivotal for advancing the company's US Product Launch Plan and brings it closer to its customers globally. Please find more details in the link below 🔗 lnkd.in/eK_s7wXb hashtag#MurslaBio hashtag#LiquidBiopsy hashtag#CancerDiagnosis hashtag#BiotechInnovation hashtag#USExpansion hashtag#HealthcareTransformation hashtag#EVTechnology

@leecronin I thought you meant VC value add for a moment

The thing that’s hidden from us because we take it for granted is causation.

🌟 NEW PAPER ALERT: Breakthrough liquid biopsy publication in @CellCellPress🌟 Excited to share that our liquid biopsy tech is featured in iScience! 🎉 Our paper, "An electro-optical platform for ultrasensitive detection of small extracellular vesicle sub-types," showcases our Nano-Extracellular Omics Sensing (NEXOS) technology. Read more: cell.com/iscience/fullt…

@KennethWWitwer @IsevOrg @IsevComms @LabWitwer @SNEVresearch @ANZSEVresearch Have a safe trip Ken. Sadly we wont be coming this year and we look forward to reading the great wrap ups at the end of the conference! (my personal favorite)

First part of the 28-hour journey to #ISEV2024 is underway. With six hours of slide-making in front of me, I’m grateful for some asparagus soup, green beans, and coffee before takeoff! @IsevOrg @IsevComms @LabWitwer @SNEVresearch @ANZSEVresearch #ExtracellularVesicles

@leecronin Well done Lee!

Can we do programmable computations in a chemical media where the chemistry does the computation? YES! This was an epic journey. Finally published: nature.com/articles/s4146…

🚨Extracellular Vesicles (EVs) & Liquid Biopsy Evolution 🚀 #MISEV2023 marks an important moment in EV research. Proud to be a co-author for @Mursla Bio! 💡Discover how #MISEV2023 is setting new standards in EV analysis & phenotyping, advancing cancer detection & personalised medicine. 🧬🔍 👉 Read more about the impact of these advancements on my blog: linkedin.com/pulse/latest-a… #EVResearch #BiomedicalInnovation #FutureOfMedicine